ALEXIS Biochemicals: JNK Inhibitor 1 (L-stereoisomer)

ALX-159-600

Revised 14-Jul-08

JNK Inhibitor 1 (L-stereoisomer)
SYNONYMS	L-JNKI1 c-Jun N-terminal Kinase Peptide Inhibitor 1, L-stereoisomer
PRODUCT LINE	Signal Transduction
PRODUCT CATEGORY	JNK [SAPK1]/Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-159-600-R100		100 µl	125.00 USD
ALX-159-600-R200		200 µl	225.00 USD

Product Specification

SEQUENCE:	GRKKRRQRRR-PP-RPKRPTTLNLFPQVPRSQD-amide
FORMULA:	C₁₆₄H₂₈₆N₆₆O₄₀
MW:	3822.5
CONCENTRATION:	1mM
PURITY:	≥97% (HPLC)
FORMULATION:	Liquid. Sterile, ready-to-use solution in PBS.
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	-20°C
HANDLING:	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Keep on ice at all times.
POSITIVE CONTROL:	Prod. No. ALX-168-009/1

Product Images

Please click on thumbnails to enlarge.

Product Description

Cell permeable JNK (c-Jun N-terminal kinase) inhibitor. For increased cell permeability the peptide was covalently linked to the 10 aa recognized by the TAT transporter. Neuroprotective agent for stroke.

Product Specific Literature References

[1] Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death: C. Bonny, et al.; Diabetes 50, 77 (2001) Abstract; Full Text
Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation: R. Reinehr, et al.; FASEB J. 17, 731 (2003) Abstract
Translation inhibitors sensitize prostate cancer cells to TRAIL-induced apoptosis by activating c-Jun N-terminal kinase: N.K. Sah, et al.; J. Biol. Chem. 278, 20593 (2003) Abstract; Full Text
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia: T. Borsello, et al.; Nat. Med. 9, 1180 (2003) Abstract
Activation of JNK in sensory neurons protects against sensory neuron cell death in diabetes and on exposure to glucose/oxidative stress in vitro: S.A. Price, et al.; Ann. NY Acad. Sci. 1010, 95 (2003)
Insulin-secreting beta-cell dysfunction induced by human lipoproteins: M.E. Roehrich, et al.; J. Biol. Chem. 278, 18368 (2003) Abstract; Full Text
Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs: M. Ishii, et al.; J. Immunol. 172, 2569 (2004) Abstract

General Information

BACKGROUND/TECHNICAL INFORMATION

A protein inhibitor named IB1 has been described that competitively blocks the interaction between JNK and c-Jun, thereby inhibiting the signalling events downstream of JNK [2,3] like c-Jun, ATF2 and ELK1 phosphorylation. To convert IB1 into cell-permeable inhibitors of JNK (JNKI peptides) the minimal 20 aa inhibitory sequence of IB1 was covalently linked to the 10 amino acids recognized by TAT transporter [4].
The L-JNKI1 and the protease resistant D-JNKI1 peptides represent the only potent inhibitors that are specific for JNK (JNK1, JNK2 and JNK3). Different from chemical inhibitors that directly affect kinase activity e.g. by competing with the ATP-binding site of the protein kinase, JNKI1 rather inhibits the interaction between JNK and its substrate, resulting in a JNK K.O. phenotype. In contrast to pure diffusion the TAT-peptides are actively transported into cells, where they remain until their proteolytic degradation. They can be used for in vitro as well as for in vivo applications (IC50~1µM).
D-JNKI1 is the only form found to be active on neuronal cells, probably due to a high level of proteolytic degradation of the L-stereoisomer (T. Borsello and C. Bonny; unpublished data). As these peptides tend to be toxic in neurons above concentrations of 5µM, it is recommended to use concentrations of ~1µM or less. When interpreting results of c-Jun inhibition, one should also note that a number of other c-Jun kinases are thought to contribute to c-Jun phosphorylation (C. Bonny, personal communication).

*For in vivo applications in mice it is suggested to start with 30-50µl of a 1mM stock solution administered intraperitoneally. Cellular uptake of L-JNKI1 peptides can now be confirmed using the FITC-conjugated L-TAT control peptide (Prod. No. ALX-168-009F).
Note: L-TAT control peptides should only be used with L-JNKI1.

General Literature References

[2] IB1, a JIP-1-related nuclear protein present in insulin-secreting cells: C. Bonny, et al.; J. Biol. Chem. 273, 1843 (1998) Abstract; Full Text
[3] A cytoplasmic inhibitor of the JNK signal transduction pathway: M. Dickens, et al.; Science 277, 693 (1997) Abstract
[4] In vivo protein transduction: delivery of a biologically active protein into the mouse: S.R. Schwarze, et al.; Science 285, 1569 (1999) Abstract